MCID: CRT033
MIFTS: 52

Corticobasal Degeneration

Categories: Rare diseases, Neuronal diseases

Aliases & Classifications for Corticobasal Degeneration

MalaCards integrated aliases for Corticobasal Degeneration:

Name: Corticobasal Degeneration 53 54 29 73
Corticobasal Syndrome 53 59
Cortical-Basal Ganglionic Degeneration 53
Cortico-Basal Ganglionic Degeneration 53
Cbgd 53

Classifications:

Orphanet: 59  
Rare neurological diseases


External Ids:

Orphanet 59 ORPHA454887
ICD10 via Orphanet 34 G31.0
UMLS 73 C0393570

Summaries for Corticobasal Degeneration

NINDS : 54 Corticobasal degeneration is a progressive neurological disorder characterized by nerve cell loss and atrophy (shrinkage) of multiple areas of the brain including the cerebral cortex and the basal ganglia. Corticobasal degeneration progresses gradually. Initial symptoms, which typically begin at or around age 60, may first appear on one side of the body (unilateral), but eventually affect both sides as the disease progresses. Symptoms are similar to those found in Parkinson disease, such as poor coordination, akinesia (an absence of movements), rigidity (a resistance to imposed movement),disequilibrium (impaired balance); and limb dystonia (abnormal muscle postures). Other symptoms such as cognitive and visual-spatial impairments, apraxia (loss of the ability to make familiar, purposeful movements), hesitant and halting speech, myoclonus (muscular jerks), and dysphagia (difficulty swallowing) may also occur. An individual with corticobasal degeneration eventually becomes unable to walk.

MalaCards based summary : Corticobasal Degeneration, also known as corticobasal syndrome, is related to frontotemporal lobar degeneration with tdp43 inclusions, grn-related and semantic dementia. An important gene associated with Corticobasal Degeneration is MAPT (Microtubule Associated Protein Tau), and among its related pathways/superpathways are NFAT and Cardiac Hypertrophy and Pathways in cancer. The drugs Iodine and cadexomer iodine have been mentioned in the context of this disorder. Affiliated tissues include cortex, brain and tongue, and related phenotypes are Decreased viability with paclitaxel and Decreased viability with paclitaxel

NIH Rare Diseases : 53 Corticobasal degeneration is characterized by the break down (degeneration) of parts of the brain, including the cerebral cortex and basal ganglia. The cerebral cortex is responsible for most of the brain's processing of information, and the basal ganglia are deep brain structures that help start and control movement. Signs and symptoms of corticobasal degeneration include poor coordination, loss of movement, rigidity, poor balance, unnatural posturing of the muscles, intellectual (cognitive) impairment, speech impairment, muscular jerks, and difficulty swallowing. These symptoms develop and worsen over time. Currently the cause of corticobasal degeneration is not known. Treatment depends on the symptoms in each person. People with corticobasal degeneration usually do not survive beyond an average of 7 years after symptoms begin. Aspiration pneumonia or other complications are usually the cause of death.

Wikipedia : 76 Corticobasal degeneration (CBD) or corticobasal ganglionic degeneration (CBGD) is a rare, progressive... more...

Related Diseases for Corticobasal Degeneration

Diseases related to Corticobasal Degeneration via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Related Disease Score Top Affiliating Genes
1 frontotemporal lobar degeneration with tdp43 inclusions, grn-related 32.9 MAPT RPS27A
2 semantic dementia 32.7 MAPT RPS27A TARDBP
3 pick disease of brain 32.6 CRYAB MAPT RPS27A TARDBP
4 frontotemporal dementia 32.1 CRYAB LRRK2 MAPT RPS27A TARDBP
5 supranuclear palsy, progressive, 1 31.4 LRRK2 MAPT MOBP RPS27A TARDBP
6 dementia 30.3 GBA LRRK2 MAPT TARDBP
7 movement disease 30.2 GBA LRRK2 MAPT
8 progressive supranuclear palsy-corticobasal syndrome 12.1
9 classic progressive supranuclear palsy syndrome 10.8
10 apraxia 10.5
11 leukoencephalopathy, hereditary diffuse, with spheroids 10.5 CRYAB MAPT RPS27A
12 alzheimer disease 10.5
13 aphasia 10.4
14 frontotemporal dementia with parkinsonism-17 10.4
15 cerebritis 10.4
16 hereditary late-onset parkinson disease 10.4 GBA LRRK2
17 parkinson disease 2, autosomal recessive juvenile 10.4 LRRK2 UCHL1
18 inclusion body myositis 10.3 MAPT RPS27A TARDBP
19 postencephalitic parkinson disease 10.3 LRRK2 MAPT TARDBP
20 myoclonus 10.3
21 neuronitis 10.3
22 multiple system atrophy 1 10.2
23 tremor 10.2 GBA LRRK2 MAPT
24 creutzfeldt-jakob disease 10.1
25 dystonia 10.1
26 synucleinopathy 10.1 GBA LRRK2 MAPT
27 parkinson disease 3, autosomal dominant 10.0 LRRK2 MAPT
28 amyotrophic lateral sclerosis 1 9.9
29 basal ganglia calcification 9.9
30 lateral sclerosis 9.9
31 rem sleep behavior disorder 9.9
32 progressive non-fluent aphasia 9.9
33 depression 9.9
34 central nervous system disease 9.9 LRRK2 MAPT TARDBP
35 stiff-person syndrome 9.8
36 hydrocephalus, normal-pressure 9.8
37 paine syndrome 9.8
38 aging 9.8
39 apraxia of eyelid opening 9.8
40 hydrocephalus 9.8
41 pulmonary fibrosis 9.8
42 arachnoiditis 9.8
43 parametritis 9.8
44 neuroleptic malignant syndrome 9.8
45 olivopontocerebellar atrophy 9.8
46 antiphospholipid syndrome 9.8
47 complex regional pain syndrome 9.8
48 striatonigral degeneration 9.8
49 alien hand syndrome 9.8
50 arachnoid cysts 9.8

Graphical network of the top 20 diseases related to Corticobasal Degeneration:



Diseases related to Corticobasal Degeneration

Symptoms & Phenotypes for Corticobasal Degeneration

GenomeRNAi Phenotypes related to Corticobasal Degeneration according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with paclitaxel GR00179-A-1 9.02 MTOR RPS6KB1
2 Decreased viability with paclitaxel GR00179-A-2 9.02 MTOR
3 Decreased viability with paclitaxel GR00179-A-3 9.02 MTOR RPS6KB1

MGI Mouse Phenotypes related to Corticobasal Degeneration:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.29 CFL1 CRYAB GBA HSPB2 LRRK2 MAPT
2 cellular MP:0005384 10.29 LRRK2 MAPT MTOR PITX3 ROCK1 ROCK2
3 cardiovascular system MP:0005385 10.27 CFL1 GBA HSPB2 LRRK2 MAPT MTOR
4 homeostasis/metabolism MP:0005376 10.22 CFL1 GBA KIF13B LRRK2 MAPT MTOR
5 growth/size/body region MP:0005378 10.2 GBA MAPT MTOR PITX3 ROCK1 ROCK2
6 hematopoietic system MP:0005397 10.17 GBA LRRK2 MAPT MTOR PITX3 ROCK1
7 immune system MP:0005387 10.11 CSF3 GBA LRRK2 MAPT MTOR PITX3
8 integument MP:0010771 9.97 LRRK2 MAPT PITX3 ROCK1 SOS1 UCHL1
9 nervous system MP:0003631 9.93 ROCK2 SOS1 TARDBP UCHL1 CFL1 GBA
10 muscle MP:0005369 9.86 CRYAB MAPT MTOR ROCK1 ROCK2 RPS6KB1
11 no phenotypic analysis MP:0003012 9.56 CFL1 KIF13B LRRK2 MAPT MTOR PITX3
12 renal/urinary system MP:0005367 9.17 CFL1 CSF3 LRRK2 MAPT MTOR ROCK1

Drugs & Therapeutics for Corticobasal Degeneration

Drugs for Corticobasal Degeneration (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 31)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iodine Approved, Investigational Phase 4 7553-56-2 807
2 cadexomer iodine Phase 4
3 Pharmaceutical Solutions Phase 4
4 Calamus Nutraceutical Phase 4
5
Pimavanserin Approved, Investigational Phase 3 706779-91-1 16058810
6
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 2, Phase 3 303-98-0 5281915
7 Ubiquinone Phase 2, Phase 3
8 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
9 Micronutrients Phase 2, Phase 3
10 Trace Elements Phase 2, Phase 3
11 Tranquilizing Agents Phase 3,Phase 1,Phase 2
12 Vitamins Phase 2, Phase 3
13 Psychotropic Drugs Phase 3,Phase 1,Phase 2
14 Serotonin Agents Phase 3
15 Neurotransmitter Agents Phase 3
16 Antiparkinson Agents Phase 3
17 Antipsychotic Agents Phase 3
18
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
19 Lithium carbonate Phase 1, Phase 2 554-13-2
20 Fluorodeoxyglucose F18 Phase 2
21 Antidepressive Agents Phase 1, Phase 2
22 Radiopharmaceuticals Phase 2
23 Antimanic Agents Phase 1, Phase 2
24 taxane Phase 1
25
Carbidopa Approved 28860-95-9 34359 38101
26
Ropinirole Approved, Investigational 91374-20-8, 91374-21-9 5095 497540
27
Pramipexole Approved, Investigational 104632-26-0 59868 119570
28
Entacapone Approved, Investigational 130929-57-6 5281081
29
Levodopa Approved 59-92-7 6047
30
Amantadine Approved 768-94-5 2130
31 Vaccines Not Applicable

Interventional clinical trials:

(show all 38)
# Name Status NCT ID Phase Drugs
1 DaTSCAN Imaging in Aging and Neurodegenerative Disease Enrolling by invitation NCT01453127 Phase 4 I-123 Ioflupane solution injection prior to SPECT scan (DaTscan)
2 Effects of Coenzyme Q10 in PSP and CBD Completed NCT00532571 Phase 2, Phase 3 CoQ10
3 Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis Recruiting NCT03325556 Phase 3 Placebo;Pimavanserin 34 mg;Pimavanserin 20 mg
4 A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration Completed NCT00703677 Phase 1, Phase 2 Lithium
5 Electrical Polarization of the Brain in Corticobasal Syndrome Completed NCT00273897 Phase 2
6 Davunetide (AL-108) in Predicted Tauopathies - Pilot Study Completed NCT01056965 Phase 2 davunetide (AL-108, NAP);Placebo nasal spray
7 The Differential Diagnosis of Parkinson's Disease and Parkinsonism by Positron-emission Tomography Completed NCT01824056 Phase 2 18F-FDG
8 Novel Neuroimage Study in Tauopathies With Parkinsonism Active, not recruiting NCT03386669 Phase 2 F-18
9 Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers Completed NCT02167594 Phase 1 18F-AV-1451;florbetapir F18
10 Safety Study of TPI-287 to Treat CBS and PSP Active, not recruiting NCT02133846 Phase 1 TPI 287 2 mg/m2;TPI-287 20 mg/m2;Placebo;TPI-287 6.3 mg/m2
11 Parkinson's Disease, Diagnostic Observations (PADDO) Unknown status NCT01249768
12 Innovative Biomarkers in Alzheimer's Disease and Frontotemporal Dementia (FTD): Preventative and Personalized Unknown status NCT01403519
13 Repetitive Transcranial Magnetic Stimulation (TMS) for Progressive Supranuclear Palsy and Corticobasal Degeneration Completed NCT01174771
14 Study of Tongue Pressures Completed NCT00013832
15 PROgressive Supranuclear Palsy CorTico-Basal Syndrome Multiple System Atrophy Longitudinal Study UK Recruiting NCT02778607
16 4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2 Recruiting NCT02966145
17 More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease Recruiting NCT03076671 Not Applicable
18 Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) Recruiting NCT02365922
19 Smell, Voice and Nasal Swabs as Markers for Neuro-degenerative Disorders Recruiting NCT03299062 Not Applicable
20 Gait Analysis in Neurological Disease Recruiting NCT02994719 Anti-Parkinson medication
21 Defining Phenotypes of Movement Disorders :Parkinson's Plus Disorders (PD), Essential Tremor (ET), Cortical Basal Degeneration (CBD), Multiple Systems Atrophy (MSA), Magnetoencephalography. Recruiting NCT02132052
22 ADDIA Proof-of-Performance Clinical Study Recruiting NCT03030586
23 Positron Emission Tomography (PET) Imaging of Tau Pathology in Neurodegenerative Disease Recruiting NCT03143374
24 Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Recruiting NCT03225144
25 The Swedish BioFINDER 2 Study Recruiting NCT03174938 Not Applicable
26 Diagnosing Frontotemporal Lobar Degeneration Recruiting NCT02964637
27 In-Home Care for Patients With PSP and Related Disorders Recruiting NCT03552484 Not Applicable
28 Early-onset Alzheimer's Disease Phenotypes: Neuropsychology and Neural Networks Recruiting NCT03153371
29 Genetic Characterization of Movement Disorders and Dementias Recruiting NCT02014246
30 Vaccination Uptake (VAX) in PD Recruiting NCT02874274 Not Applicable
31 Comprehensive Assessment of Neurodegeneration and Dementia Recruiting NCT03402919
32 4 Repeat Tauopathy Neuroimaging Initiative Active, not recruiting NCT01804452
33 Study for the Early Diagnosis of Parkinson's Disease Active, not recruiting NCT02283073
34 The Sunnybrook Dementia Study: Mapping Brain Changes in Alzheimer's, Vascular and Other Dementias Active, not recruiting NCT01800214
35 SudoScan as a Biomarker of Parkinson's Disease Active, not recruiting NCT02767037 Not Applicable
36 Human CNS Tau Kinetics in Tauopathies Enrolling by invitation NCT03545126
37 Brain Network Activation in Patients With Movement Disorders Not yet recruiting NCT03269201
38 Autologous Stem/Stromal Cells in Neurological Disorders and Disease Not yet recruiting NCT03297177 Not Applicable

Search NIH Clinical Center for Corticobasal Degeneration

Genetic Tests for Corticobasal Degeneration

Genetic tests related to Corticobasal Degeneration:

# Genetic test Affiliating Genes
1 Corticobasal Degeneration 29

Anatomical Context for Corticobasal Degeneration

MalaCards organs/tissues related to Corticobasal Degeneration:

41
Cortex, Brain, Tongue, Eye, Spinal Cord, Thalamus

Publications for Corticobasal Degeneration

Articles related to Corticobasal Degeneration:

(show top 50) (show all 423)
# Title Authors Year
1
Clinical and imaging progression over 10 years in a patient with primary progressive apraxia of speech and autopsy-confirmed corticobasal degeneration. ( 29799310 )
2018
2
Clinical Routine FDG-PET Imaging of Suspected Progressive Supranuclear Palsy and Corticobasal Degeneration: A Gatekeeper for Subsequent Tau-PET Imaging? ( 29973914 )
2018
3
Corticobasal degeneration: key emerging issues. ( 29063240 )
2018
4
Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype. ( 29926172 )
2018
5
Cognitive reserve maps the core loci of neurodegeneration in Corticobasal Degeneration. ( 29931723 )
2018
6
Disentangling the neural correlates of corticobasal syndrome and corticobasal degeneration with systematic and quantitative ALE meta-analyses. ( 28649612 )
2017
7
Apathy in corticobasal degeneration: possible parietal involvement. ( 29306357 )
2017
8
Differentiating cognitive impairment due to corticobasal degeneration and Alzheimer disease. ( 28235814 )
2017
9
An autopsied case of corticobasal degeneration presenting with frontotemporal dementia followed by myoclonus. ( 28707717 )
2017
10
Cognitive dysfunction in corticobasal degeneration. ( 28813088 )
2017
11
The Neuropsychology (Broadly Conceived) of Multiple System Atrophy, Progressive Supranuclear Palsy, and Corticobasal Degeneration. ( 28961692 )
2017
12
Levodopa-responsive depression associated with corticobasal degeneration: a case report. ( 28458551 )
2017
13
Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia. ( 28271184 )
2017
14
Features of Patients With Nonfluent/Agrammatic Primary Progressive Aphasia With Underlying Progressive Supranuclear Palsy Pathology or Corticobasal Degeneration. ( 27111692 )
2016
15
Visual signs and symptoms of corticobasal degeneration. ( 27553583 )
2016
16
Rho Kinase Inhibition as a Therapeutic for Progressive Supranuclear Palsy and Corticobasal Degeneration. ( 26818518 )
2016
17
Study of LRRK2 variation in tauopathy: Progressive supranuclear palsy and corticobasal degeneration. ( 27709685 )
2016
18
Multimodal evaluation demonstrates in vivo (18)F-AV-1451 uptake in autopsy-confirmed corticobasal degeneration. ( 27815633 )
2016
19
Progressive Supranuclear Palsy and Corticobasal Degeneration: Pathophysiology and Treatment Options. ( 27526039 )
2016
20
Progressive supranuclear palsy and corticobasal degeneration: Diagnostic challenges and clinicopathological considerations. ( 27561438 )
2016
21
Fulminant corticobasal degeneration: Agrypnia excitata in corticobasal syndrome. ( 26873956 )
2016
22
Incidental corticobasal degeneration. ( 27461552 )
2016
23
[18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration. ( 27645292 )
2016
24
Tau pathology in aged cynomolgus monkeys is progressive supranuclear palsy/corticobasal degeneration- but not Alzheimer disease-like -Ultrastructural mapping of tau by EDX. ( 27842611 )
2016
25
Poster 332 Corticobasal Degeneration with Spastic Left Hemiparesis, Dystonic Posturing, and Rigidity: A Case Report. ( 27673088 )
2016
26
Diagnoses of corticobasal syndrome and corticobasal degeneration. ( 26876110 )
2016
27
Autophagic and lysosomal defects in human tauopathies: analysis of post-mortem brain from patients with familial Alzheimer disease, corticobasal degeneration and progressive supranuclear palsy. ( 26936765 )
2016
28
Astrogliopathy predominates the earliest stage of corticobasal degeneration pathology. ( 27797812 )
2016
29
Dopamine transporter imaging as a diagnostic modality for atypical Alzheimer's disease mimicking corticobasal degeneration. ( 26781839 )
2016
30
Presymptomatic anterior frontal involvement in corticobasal degeneration. ( 27913406 )
2016
31
Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer's disease or corticobasal degeneration brains. ( 25534024 )
2015
32
Pathological features of preclinical or early clinical stages of corticobasal degeneration: a comparison with advanced cases. ( 25708668 )
2015
33
F-18 fluoro-d-glucose positron emission tomography/computed tomography in a patient with corticobasal degeneration. ( 25829747 )
2015
34
Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. ( 26077951 )
2015
35
Key emerging issues in progressive supranuclear palsy and corticobasal degeneration. ( 25701010 )
2015
36
Therapeutic interventions in parkinsonism: Corticobasal degeneration. ( 26382843 )
2015
37
Corticobasal degeneration: clinical characteristics and multidisciplinary therapeutic approach in 26 patients. ( 25917399 )
2015
38
Progressive Dopamine Transporter Binding Loss in Autopsy-Confirmed Corticobasal Degeneration. ( 26485425 )
2015
39
An autopsied case of corticobasal degeneration showing severe cerebral atrophy over a protracted disease course of 16 years. ( 25516199 )
2014
40
Astrocytic inclusions in progressive supranuclear palsy and corticobasal degeneration. ( 25124031 )
2014
41
Corticobasal degeneration. ( 24963675 )
2014
42
A disease-specific metabolic brain network associated with corticobasal degeneration. ( 25208922 )
2014
43
Argyrophilic grains are reliable disease-specific features of corticobasal degeneration. ( 24335531 )
2014
44
In vivo decreased dopamine transporter uptake in corticobasal degeneration presenting with primary progressive aphasia without parkinsonism. ( 24919427 )
2014
45
Diagnosis and treatment of corticobasal degeneration. ( 24469408 )
2014
46
Managing Advanced Progressive Supranuclear Palsy and Corticobasal Degeneration in a Palliative Care Unit: Admission Triggers and Outcomes. ( 25550443 )
2014
47
Corticobasal degeneration initially developing motor versus non-motor symptoms: a comparative clinicopathological study. ( 25186621 )
2014
48
Concomitant accumulation of I+-synuclein and TDP-43 in a patient with corticobasal degeneration. ( 25209854 )
2014
49
Apraxia in anti-GAD associated stiff person syndrome: Link to corticobasal degeneration? ( 25100431 )
2014
50
Validation of the new consensus criteria for the diagnosis of corticobasal degeneration. ( 24521567 )
2014

Variations for Corticobasal Degeneration

Expression for Corticobasal Degeneration

Search GEO for disease gene expression data for Corticobasal Degeneration.

Pathways for Corticobasal Degeneration

Pathways related to Corticobasal Degeneration according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.68 MTOR ROCK1 ROCK2 RPS6KB1 SOS1
2 12.64 MTOR ROCK1 ROCK2 RPS6KB1 SOS1
3 12.41 LRRK2 MAPT RPS27A TARDBP UCHL1
4 12.37 CFL1 MAPT ROCK1 ROCK2
5
Show member pathways
12.22 MTOR ROCK1 ROCK2 RPS6KB1 SOS1
6
Show member pathways
12.19 MAPT ROCK1 ROCK2 SOS1
7 11.92 CFL1 MAPT MTOR RPS6KB1
8 11.87 CFL1 MTOR ROCK1 RPS6KB1 SOS1
9 11.79 MTOR RPS6KB1 SOS1
10
Show member pathways
11.5 MTOR RPS6KB1 SOS1
11 11.4 HSPB2 MTOR ROCK1 ROCK2 RPS6KB1 SOS1
12
Show member pathways
11.36 CFL1 ROCK1 ROCK2 SOS1
13 11.34 MTOR ROCK1 ROCK2 RPS6KB1 SOS1
14 11.22 CFL1 ROCK1 ROCK2
15 11.11 MTOR RPS6KB1 SOS1
16 11.07 CFL1 ROCK1 ROCK2 RPS6KB1
17
Show member pathways
10.76 MTOR RPS6KB1
18 10.71 MTOR RPS6KB1

GO Terms for Corticobasal Degeneration

Cellular components related to Corticobasal Degeneration according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuronal cell body GO:0043025 9.73 LRRK2 MAPT MTOR PITX3 SOS1 UCHL1
2 axon GO:0030424 9.72 CRYAB KIF13B LRRK2 MAPT UCHL1
3 mitochondrial outer membrane GO:0005741 9.67 LRRK2 MTOR RPS27A RPS6KB1
4 cytoplasm GO:0005737 9.55 CFL1 CRYAB HSPB2 KIF13B LRRK2 MAPT
5 myelin sheath GO:0043209 9.35 CRYAB MOBP PGAM1 RPS27A UCHL1
6 cytosol GO:0005829 10.03 CFL1 CRYAB HSPB2 KIF13B LRRK2 MAPT

Biological processes related to Corticobasal Degeneration according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 Rho protein signal transduction GO:0007266 9.77 CFL1 ROCK1 ROCK2
2 regulation of cellular response to heat GO:1900034 9.77 CRYAB MAPT MTOR
3 peptidyl-threonine phosphorylation GO:0018107 9.76 LRRK2 MTOR ROCK2
4 negative regulation of protein phosphorylation GO:0001933 9.75 LRRK2 MTOR TARDBP
5 protein phosphorylation GO:0006468 9.73 CFL1 LRRK2 MTOR ROCK1 ROCK2 RPS6KB1
6 regulation of actin cytoskeleton organization GO:0032956 9.72 MTOR ROCK1 ROCK2
7 regulation of macroautophagy GO:0016241 9.71 GBA MTOR UCHL1
8 regulation of autophagy GO:0010506 9.7 LRRK2 MAPT ROCK1
9 cellular response to starvation GO:0009267 9.65 GBA LRRK2 MTOR
10 regulation of stress fiber assembly GO:0051492 9.64 ROCK1 ROCK2
11 TOR signaling GO:0031929 9.63 MTOR RPS6KB1
12 regulation of keratinocyte differentiation GO:0045616 9.63 ROCK1 ROCK2
13 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.63 ROCK1 ROCK2 RPS27A
14 regulation of dendritic spine morphogenesis GO:0061001 9.62 CFL1 LRRK2
15 negative regulation of macroautophagy GO:0016242 9.61 LRRK2 MTOR
16 regulation of protein metabolic process GO:0051246 9.61 GBA ROCK2
17 negative regulation of neuron death GO:1901215 9.58 CSF3 GBA LRRK2
18 negative regulation of protein homooligomerization GO:0032463 9.57 CRYAB GBA
19 axonal transport of mitochondrion GO:0019896 9.56 MAPT UCHL1
20 intracellular distribution of mitochondria GO:0048312 9.51 LRRK2 MAPT
21 regulation of mitochondrial fission GO:0090140 9.49 LRRK2 MAPT
22 peptidyl-serine phosphorylation GO:0018105 9.46 LRRK2 MTOR ROCK2 RPS6KB1
23 regulation of establishment of endothelial barrier GO:1903140 9.43 ROCK1 ROCK2
24 negative regulation of bicellular tight junction assembly GO:1903347 9.37 ROCK1 ROCK2
25 negative regulation of myosin-light-chain-phosphatase activity GO:0035509 9.32 ROCK1 ROCK2
26 neuron projection arborization GO:0140058 8.96 LRRK2 ROCK1
27 response to amino acid GO:0043200 8.8 CFL1 MTOR RPS6KB1
28 negative regulation of apoptotic process GO:0043066 10.02 CFL1 CRYAB PRDX5 RPS27A RPS6KB1

Molecular functions related to Corticobasal Degeneration according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 microtubule binding GO:0008017 9.56 CRYAB KIF13B LRRK2 MAPT
2 protein kinase activity GO:0004672 9.55 LRRK2 MTOR ROCK1 ROCK2 RPS6KB1
3 protein serine/threonine kinase activity GO:0004674 9.35 LRRK2 MTOR ROCK1 ROCK2 RPS6KB1
4 Rho GTPase binding GO:0017048 8.8 LRRK2 ROCK1 ROCK2
5 protein binding GO:0005515 10.25 CFL1 CRYAB GBA HSPB2 KIF13B LRRK2

Sources for Corticobasal Degeneration

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....